US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class III · Low risk Terminated

Progesterone SR 100 mg Capsules

Reason Labeling Not Elsewhere Classified: Misbranding.

Right Value Drug Stores, Inc. NDC 99999-0104-55 D-0240-2019
Class II · Moderate risk Terminated

Lidocaine 1% + Epinephrine 1:100

Reason Subpotent drug: During testing of the retention sample, the firm discovered that the product was sub-potent.

RXQ Compounding LLC D-0130-2019
Class II · Moderate risk Terminated

Nystatin and Triamcinolone Acetonide Cream

Reason Failed stability specifications - An out of specification result was observed for the test parameter : composition of Nystatin during stability testing.

Dr. Reddy's Laboratories, Inc. NDC 43598-431-44 D-0007-2019
Class II · Moderate risk Terminated

Clozapine Orally Disintegrating Tablets

Reason Failed Disintegration Specifications: Out-of-specification disintegration test result obtained during routine stability testing.

Teva Pharmaceuticals USA NDC 0093-5416-01 D-0001-2019
Class II · Moderate risk Terminated

Meropenem for Injection

Reason Lack of assurance of sterility: loss of container integrity.

Pfizer Inc. D-0095-2019
Class II · Moderate risk Terminated

Clonazepam Orally Disintegrating Tablets USP

Reason Failed Stability Specifications: Out-of-specification test result for water content obtained during routine stability testing.

Teva Pharmaceuticals USA NDC 0555-0098-96 D-0082-2019
Class II · Moderate risk Terminated

Glipizide XL

Reason CGMP Deviations; rejected product was used to manufacture final bulk lot

Pfizer Inc. NDC 59762-0541-2 D-0010-2019
Class II · Moderate risk Terminated

Bumetanide Tablets

Reason Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product.

Upsher Smith Laboratories, Inc. NDC 0832-0542-11 D-0281-2019
Class II · Moderate risk Terminated

Bumetanide Tablets

Reason Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product.

Upsher Smith Laboratories, Inc. NDC 0832-0541-11 D-0280-2019
Class II · Moderate risk Terminated

Elelyso

Reason Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

Pfizer Inc. NDC 0069-0106-01 D-0005-2019
Class III · Low risk Terminated

Altavera Levonorgestrel and Ethinyl Estradiol Tablets

Reason Labeling: Not Elsewhere Classified: mislabeling of the Altavera generic name on the packaging component that may cause confusion.

Xiromed LLC NDC 70700-116-85 D-0016-2019
Class II · Moderate risk Terminated

SparkleFresh Fluoride Toothpaste

Reason Microbial Contamination of Non-Sterile Product

Medline Industries Inc NDC 53329-083-92 D-0247-2019
Class III · Low risk Terminated

treatNOW ABILIFY

Reason Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Otsuka Pharmaceutical Development & Commercialization, Inc. D-0018-2019
Class III · Low risk Terminated

treatNOW ABILIFY

Reason Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Otsuka Pharmaceutical Development & Commercialization, Inc. D-0017-2019
Class I · High risk Terminated

robaxin-750

Reason Labeling: Incorrect Instructions: Dosage information on the immediate container label incorrectly states "Two to four tablets four times daily." rather than the correct dosage of "Two tablets three times daily."

Endo Pharmaceuticals, Inc. NDC 52244-449-10 D-0009-2019
Class III · Low risk Terminated

Fenofibrate Tablets

Reason Presence of Foreign Tablet/Capsule: A foreign identified as Valacyclovir tablet 500 mg was co-mingled in a bottle containing Fenofibrate Tablets, USP 145 mg.

Hetero Labs, Ltd. - Unit III NDC 31722-596-90 D-1211-2018
Class III · Low risk Terminated

Zoledronic Acid Injection

Reason Failed Impurities/Degradation Specifications: OOS for unknown impurities.

Dr. Reddy's Laboratories, Inc. NDC 43598-331-11 D-0104-2019
Class III · Low risk Terminated

Zoledronic Acid Injection

Reason Failed Impurities/Degradation Specifications: OOS for unknown impurities.

Dr. Reddy's Laboratories, Inc. NDC 55111-688-52 D-0103-2019
Class II · Moderate risk Terminated

Lamotrigine Extended-Release Tablets

Reason Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.

Torrent Pharma Inc. D-1204-2018
Class II · Moderate risk Terminated

Zinc Sulfate 1 mg/mL MDV Injectable

Reason Lack of Assurance of Sterility

Pharm D Solutions, LLC NDC 69699-1418-10 D-0212-2019